Cargando…
Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are a promising second‐line treatment strategy for type 2 diabetes mellitus (T2DM) with a developing landscape of both beneficial cardio‐ and nephroprotective properties and emerging adverse drug reactions (ADRs) including diabetic ketoacidosis (DK...
Autores principales: | Matharu, Karan, Chana, Kiran, Ferro, Charles J., Jones, Alan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480305/ https://www.ncbi.nlm.nih.gov/pubmed/34586753 http://dx.doi.org/10.1002/prp2.867 |
Ejemplares similares
-
Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
por: Jones, Lauren, et al.
Publicado: (2022) -
The kinase polypharmacology landscape of clinical PARP inhibitors
por: Antolin, Albert A., et al.
Publicado: (2020) -
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
por: Ciceri, Pietro, et al.
Publicado: (2014) -
The Polypharmacological Effects of Cannabidiol
por: Castillo-Arellano, Jorge, et al.
Publicado: (2023) -
Advances in Computational Polypharmacology
por: Feldmann, Christian, et al.
Publicado: (2022)